Invited Discussant: Perioperative EV + Pembrolizumab in #MIBC – KEYNOTE-905 and KEYNOTE-B15 ctDNA Analyses. Presented by @MTeoMD @MSKCancerCenter. #ESMO26 written coverage by @chav

UroToday.com· @urotoday · X·2026-10-24 03:45· 2 天前评分70

正文 · 机器翻译

特邀讨论嘉宾：围手术期 EV + Pembrolizumab 在 #MIBC 中的应用——KEYNOTE-905 和 KEYNOTE-B15 ctDNA 分析。由 @MTeoMD @MSKCancerCenter 汇报。#ESMO26 文字报道由 @chavarriagaj @PSH_Urology 撰写 > https://bit.ly/3TYzso1 #BladderCancer #Immunotherapy @myESMO

425 浏览 · 4 赞 · 5 转发 · 0 回复

会议摘要

4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

来源：UroToday.com · x.com